ResMed Inc. Continues to draw attention from investors across Europe as the global leader in sleep apnea therapy demonstrates sustained growth potential in a market shaped by rising awareness of sleep disorders and technological innovation in respiratory care. Headquartered in San Diego, California, the company has built a dominant position in the diagnosis and treatment of sleep-disordered breathing, particularly obstructive sleep apnea (OSA), a condition affecting an estimated 936 million adults worldwide according to the World Health Organization’s 2019 global prevalence study.
For shareholders in Germany, Austria, and Switzerland, ResMed’s stock offers exposure to a U.S.-based healthcare technology firm with recurring revenue streams from devices, masks, and digital health platforms. The company’s therapeutic solutions—including continuous positive airway pressure (CPAP) machines, auto-adjusting devices, and ventilators—are prescribed in over 120 countries and supported by a growing body of clinical evidence linking effective OSA treatment to reduced risks of hypertension, stroke, and cardiovascular events.
Recent financial performance underscores the durability of demand. In its fiscal year 2024, ResMed reported revenue of $4.1 billion, representing a 7% increase compared to the prior year, driven by strong growth in both its sleep and respiratory care segments. The company’s gross margin remained stable at approximately 58%, reflecting operational efficiency despite ongoing supply chain pressures in the medical device sector. These figures were disclosed in ResMed’s annual report filed with the U.S. Securities and Exchange Commission on August 28, 2024.
Analysts at major financial institutions have highlighted the structural tailwinds supporting long-term growth. According to a January 2024 report by Morgan Stanley, the global sleep apnea therapeutics market is projected to expand at a compound annual growth rate (CAGR) of 8.5% through 2030, fueled by increasing diagnosis rates, aging populations, and broader recognition of OSA as a public health concern. The firm noted that ResMed’s early investment in connected care platforms—such as its AirView™ remote monitoring system—gives it a competitive edge in value-based care models increasingly adopted by health systems in North America and Europe.
ResMed’s innovation pipeline remains active. In March 2024, the company received U.S. Food and Drug Administration (FDA) clearance for its AirSense™ 11 AutoSet device with integrated oximetry, enabling more comprehensive tracking of nocturnal oxygen levels alongside therapy adherence. This advancement supports clinicians in identifying patients who may benefit from supplemental oxygen or alternative therapies, particularly those with comorbid conditions like chronic obstructive pulmonary disease (COPD) or heart failure.
The company’s commitment to accessibility is evident in its efforts to reduce barriers to diagnosis. Through its SleepCoach™ digital platform and partnerships with primary care providers, ResMed supports home-based sleep testing initiatives that aim to identify undiagnosed cases. Studies suggest that up to 80% of moderate to severe OSA cases remain undetected, presenting both a clinical challenge and a market opportunity for companies offering scalable screening tools.
Environmental, social, and governance (ESG) considerations are also shaping investor perception. ResMed has committed to achieving net-zero greenhouse gas emissions across its operations by 2050, with interim targets for 2030 aligned with the Science Based Targets initiative. The company reports progress through annual sustainability disclosures, including a 2023 reduction in scope 1 and 2 emissions by 12% compared to its 2019 baseline, as detailed in its ESG report published in June 2024.
Despite these strengths, risks persist. Competitive pressure from emerging players offering lower-cost alternatives, particularly in price-sensitive markets, could influence pricing dynamics. Reimbursement policies vary significantly across countries, affecting adoption rates. In Germany, for example, statutory health insurance covers CPAP therapy under strict guidelines requiring documented apnea-hypopnea index (AHI) scores and physician authorization, a process that can delay treatment initiation.
Looking ahead, ResMed’s next major milestone is the scheduled release of its fiscal year 2025 first-quarter results on May 6, 2025. Investors will closely monitor guidance for device sales, gross margin trends, and updates on international expansion efforts, particularly in Asia-Pacific and Latin America where penetration rates remain below those in North America and Western Europe.
For readers seeking authoritative updates, ResMed’s investor relations website provides access to SEC filings, earnings call transcripts, and corporate governance documents. The company also publishes clinical white papers and real-world evidence studies through its ResMed Science Center, offering transparency into the therapeutic impact of its technologies.
As awareness of sleep health grows and healthcare systems prioritize preventive care, ResMed’s role in advancing accessible, data-informed therapy positions it at the intersection of medical innovation and public health need. The company’s ability to balance technological advancement with affordability and equity will be critical to maintaining its leadership in the evolving landscape of sleep medicine.
We invite our readers to share perspectives on the future of sleep apnea care and the role of technology in managing chronic conditions. Join the conversation by commenting below or sharing this article with colleagues interested in health innovation and investment trends in medical technology.